Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 2
Update on the use of pramipexole in the treatment of Parkinson’s disease
Authors Constantinescu R
Published 11 April 2008 Volume 2008:4(2) Pages 337—352
Radu Constantinescu
Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
Abstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.
Keywords: pramipexole, Parkinson’s disease, efficacy, adverse events
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.